Expanding Global Pharmaceutical R&D Will Unlock Blockbuster Royalty Deals

AN
AnalystHighTarget
AnalystHighTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
15 Apr 25
Updated
08 Aug 25
AnalystHighTarget's Fair Value
US$55.00
32.7% undervalued intrinsic discount
08 Aug
US$37.01
Loading
1Y
41.5%
7D
0.6%

Author's Valuation

US$55.0

32.7% undervalued intrinsic discount

AnalystHighTarget Fair Value

Shared on07 May 25
Fair value Decreased 12%

Shared on30 Apr 25

AnalystHighTarget has increased profit margin from 26.1% to 64.4% and decreased future PE multiple from 31.2x to 12.7x.

Shared on23 Apr 25
Fair value Increased 16%

AnalystHighTarget made no meaningful changes to valuation assumptions.